Aviragen Therapeutics to Present at Stifel 2016 Healthcare Conference
November 09 2016 - 4:01PM
Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical
company that is developing the next generation of antivirals, today
announced that Aviragen’s CFO & Executive Vice President Mark
Colonnese will present a corporate overview at the Stifel 2016
Healthcare Conference on Wednesday, November 16, 2016 at 2:15pm ET
in New York.
A live webcast of the presentation can be accessed under "Events
and Presentations" in the Investors section of the Company's
website at www.aviragentherapeutics.com or at
http://wsw.com/webcast/stifel5/avir.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the
discovery and development of the next generation of direct-acting
antivirals to treat infections that have limited therapeutic
options and affect a significant number of patients globally. The
Company has three product candidates in active clinical
development: vapendavir, an oral treatment for human rhinovirus
(HRV) upper respiratory infections in moderate-to-severe asthmatics
currently being evaluated in the Phase 2b SPIRITUS trial; BTA585,
an oral fusion protein inhibitor in Phase 2 development for the
treatment and prevention of respiratory syncytial virus (RSV)
infections; and BTA074, a topical antiviral treatment in Phase 2
development for condyloma caused by human papillomavirus types 6
& 11. For additional information about the Company, please
visit www.aviragentherapeutics.com.
Contacts:
Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381
mcolonnese@aviragentherapeutics.com
Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024